Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia (Certolizumab Pegol)

Trial Profile

A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia (Certolizumab Pegol)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CRADLE
  • Sponsors UCB

Most Recent Events

  • 13 Jun 2024 According to UCB media release, data of CHERISH trial having data build on previous pharmacokinetic studies CRIB and CRADLE , will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment decisions for patient populations with high unmet need
  • 25 Mar 2019 According to a UCB media release, the Health Canada has approved label updates in pregnancy and breastfeeding based on two pivotal pharmacokinetic studies (CRIB and CRADLE).
  • 22 Mar 2018 Results published in UCB the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top